Clarke K - Search Results

1

Modification of myocardial substrate use as a therapy for heart failure.

Abozguia K, Clarke K, Lee L, Frenneaux M. Abozguia K, et al. Among authors: clarke k. Nat Clin Pract Cardiovasc Med. 2006 Sep;3(9):490-8. doi: 10.1038/ncpcardio0583. Nat Clin Pract Cardiovasc Med. 2006. PMID: 16932766 Review.

2

Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.

Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K, Frenneaux M. Lee L, et al. Among authors: clarke k. Circulation. 2005 Nov 22;112(21):3280-8. doi: 10.1161/CIRCULATIONAHA.105.551457. Circulation. 2005. PMID: 16301359 Clinical Trial.

3

Changes in cardiac substrate transporters and metabolic proteins mirror the metabolic shift in patients with aortic stenosis.

Heather LC, Howell NJ, Emmanuel Y, Cole MA, Frenneaux MP, Pagano D, Clarke K. Heather LC, et al. Among authors: clarke k. PLoS One. 2011;6(10):e26326. doi: 10.1371/journal.pone.0026326. Epub 2011 Oct 18. PLoS One. 2011. PMID: 22028857 Free PMC article.

4

Chronic oral ascorbic acid therapy worsens skeletal muscle metabolism in patients with chronic heart failure.

Nightingale AK, Crilley JG, Pegge NC, Boehm EA, Mumford C, Taylor DJ, Styles P, Clarke K, Frenneaux MP. Nightingale AK, et al. Among authors: clarke k. Eur J Heart Fail. 2007 Mar;9(3):287-91. doi: 10.1016/j.ejheart.2006.06.006. Epub 2006 Oct 4. Eur J Heart Fail. 2007. PMID: 17023203 Free article. Clinical Trial.

5

Myocardial substrate metabolism in heart disease.

Evans RD, Clarke K. Evans RD, et al. Among authors: clarke k. Front Biosci (Schol Ed). 2012 Jan 1;4(2):556-80. doi: 10.2741/s285. Front Biosci (Schol Ed). 2012. PMID: 22202077 Review.

6

Evaluation of Acute Supplementation With the Ketone Ester (R)-3-Hydroxybutyl-(R)-3-Hydroxybutyrate (deltaG) in Healthy Volunteers by Cardiac and Skeletal Muscle ³¹P Magnetic Resonance Spectroscopy.

Cameron D, Soto-Mota A, Willis DR, Ellis J, Procter NEK, Greenwood R, Saunders N, Schulte RF, Vassiliou VS, Tyler DJ, Schmid AI, Rodgers CT, Malcolm PN, Clarke K, Frenneaux MP, Valkovič L. Cameron D, et al. Among authors: clarke k. Front Physiol. 2022 Jan 31;13:793987. doi: 10.3389/fphys.2022.793987. eCollection 2022. Front Physiol. 2022. PMID: 35173629 Free PMC article.

7

Mitochondria and heart failure.

Murray AJ, Edwards LM, Clarke K. Murray AJ, et al. Among authors: clarke k. Curr Opin Clin Nutr Metab Care. 2007 Nov;10(6):704-11. doi: 10.1097/MCO.0b013e3282f0ecbe. Curr Opin Clin Nutr Metab Care. 2007. PMID: 18089951 Review.

8

The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.

Lygate CA, Hulbert K, Monfared M, Cole MA, Clarke K, Neubauer S. Lygate CA, et al. Among authors: clarke k. Cardiovasc Res. 2003 Jun 1;58(3):632-7. doi: 10.1016/s0008-6363(03)00289-x. Cardiovasc Res. 2003. PMID: 12798436

9

Uncoupling proteins in human heart.

Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Murray AJ, et al. Among authors: clarke k. Lancet. 2004 Nov 13-19;364(9447):1786-8. doi: 10.1016/S0140-6736(04)17402-3. Lancet. 2004. PMID: 15541452

10

Supranormal myocardial creatine and phosphocreatine concentrations lead to cardiac hypertrophy and heart failure: insights from creatine transporter-overexpressing transgenic mice.

Wallis J, Lygate CA, Fischer A, ten Hove M, Schneider JE, Sebag-Montefiore L, Dawson D, Hulbert K, Zhang W, Zhang MH, Watkins H, Clarke K, Neubauer S. Wallis J, et al. Among authors: clarke k. Circulation. 2005 Nov 15;112(20):3131-9. doi: 10.1161/CIRCULATIONAHA.105.572990. Circulation. 2005. PMID: 16286605

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,212 results

Search Page